Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202075
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huerta, Miguel Á. | - |
dc.contributor.author | García, Miguel M. | - |
dc.contributor.author | García Parra, Beliu | - |
dc.contributor.author | Serrano Afonso, Ancor | - |
dc.contributor.author | Paniagua, Nancy | - |
dc.date.accessioned | 2023-09-21T11:15:01Z | - |
dc.date.available | 2023-09-21T11:15:01Z | - |
dc.date.issued | 2023-08-20 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | http://hdl.handle.net/2445/202075 | - |
dc.description.abstract | The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) a2d subunit inhibition (crisugabalin, mirogabalin and prega-balin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in ad-vanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN. | - |
dc.format.extent | 19 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms241612987 | - |
dc.relation.ispartof | International Journal of Molecular Sciences, 2023, vol. 24, num. 16 | - |
dc.relation.uri | https://doi.org/10.3390/ijms241612987 | - |
dc.rights | cc by (c) Huerta, Miguel Á. et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Herpes zòster | - |
dc.subject.classification | Neuropaties perifèriques | - |
dc.subject.classification | Farmacologia | - |
dc.subject.other | Shingles (Disease) | - |
dc.subject.other | Peripheral neuropathies | - |
dc.subject.other | Pharmacology | - |
dc.title | Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-18T07:29:03Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37629168 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ijms-24-12987.pdf | 1.39 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License